NCT05877872View on ClinicalTrials.gov

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions
Nasopharyngeal CarcinomaDe-escaltion Therapy
Interventions
PROCEDURE

Reduced-target resection

Patients receive surgery according to pSTV-post-IC.

PROCEDURE

Full-target resection

Patients receive surgery according to pSTV-pre-IC.

DRUG

Adjuvant immunotherapy

Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.

Trial Locations (1)

510060

RECRUITING

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

First People's Hospital of Foshan

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Sun Yat-sen University

OTHER